Jazz Pharmaceuticals (JAZZ) news
Recent news
Jardine Matheson sees 2026 underlying EPS $5.50-$5.65
Jardine Matheson Holdings Limited (JARD) has reaffirmed its full-year 2026 earnings guidance, with underlying earnings per share (EPS) expected to range between $5.50 and $5.65. This projection aligns with the company’s performance in the first quarter of 2026, which delivered results marginally…
AInvest Wire · 3d agoJazz Pharma chief commercial officer Pearce to retire by Jun 30
Jazz Pharmaceuticals announced that David Pearce, Chief Commercial Officer, will retire from the company by June 30, 2027[1]. Pearce has played a pivotal role in shaping the company’s commercial strategy and has contributed to the growth of Jazz’s global business. The company has not yet disclosed…
AInvest Wire · 6d agoJazz Pharmaceuticals PLC: RBC cuts target price to $296 from $299
RBC Capital analyst Leonid Timashev has adjusted the price target for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), reducing it to $296 from $299 while maintaining an "Outperform" rating on the shares. This update follows recent developments in the company’s oncology and neuroscience portfolios,…
AInvest Wire · 7d agoJazz Pharmaceuticals PLC: Citigroup initiates coverage with buy rating; target price $325
Citigroup has initiated coverage on Jazz Pharmaceuticals PLC (JAZZ) with a "buy" rating and a target price of $325 per share. The decision reflects the firm’s assessment of Jazz Pharmaceuticals’ recent developments, including positive data from its Ziihera program, which has positioned the company…
AInvest Wire · Sep 30, 2026ABCellera Biologics Inc.: JP Morgan initiates coverage with overweight rating; target price $17
JP Morgan has initiated coverage on AbCellera Biologics Inc. (ABCL) with an overweight rating and a target price of $17 per share, reflecting optimism around the company’s clinical progress and strategic partnerships. This aligns with recent analyst commentary that has raised the fair value…
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.